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extended rolesAbstract Background: The pharmaceutical care and ‘extended’ roles are still not practiced
optimally by community pharmacists. Several studies have discussed the practice of community
pharmacy in the UAE and have shown that most community pharmacists only counsel patients.
However, UAE, has taken initiatives to allow and prepare community pharmacists to practice
‘extended’ roles. Aim of the review: The aim was to review the current roles of community pharma-
cists in Abu Dhabi Emirate, United Arab Emirates (UAE). Objective: The objective was to encour-
age community pharmacists toward extending their practice roles. Methods: In 2010, Health
Authority Abu Dhabi (HAAD) surveyed community pharmacists, using an online questionnaire,
564 M.M. Sadek et al.on their preferences toward extending their counseling roles and their opinion of the greatest chal-
lenge facing the extension of their counseling roles. Results: Following this survey, several programs
have been developed to prepare community pharmacists to undertake these extended counseling
roles. In addition to that, HAAD redeﬁned the scope of pharmacist roles to include some
extended/enhanced roles. Abu Dhabi Health Services (SEHA) mission is to ensure reliable excellence
in healthcare. It has put clear plans to achieve this; these include increasing focus on public health
matters, developing and monitoring evidence-based clinical policies, training health professionals
to comply with international standards to deliver world-class quality care, among others. Prior to
making further plans to extend community pharmacists’ roles, and to ensure the success of these
plans, it is imperative to establish the views of community pharmacists in Abu Dhabi on practicing
extended roles and to gain understanding and information on what pharmacists see as preferred
change strategies or facilitators to change. Conclusions: In an attempt to adapt to the changes occur-
ring and to the growing needs of patients and to maximize the utilization of community pharmacists’
unique structured strategies are needed to be introduced to the community pharmacy profession.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Contents
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1.1. Background
Decades ago, community pharmacists exclusively practiced cer-
tain roles such as compounding, marketing-selling, and dispens-
ing medications. This gave them specialization and autonomy
as healthcare professionals. However, rapid advances in tech-
nology, research, education, the changing cultural/socioeco-
nomic status of many populations and the escalating needs
and requirements of patients have fostered many changes which
eventually led to the minimized and gradual beating of special-
ization of pharmacists in these traditional roles (Gilbert, 1998;
Bush et al., 2009; Scahill et al., 2010; McDonald et al., 2010).
1.2. Summary of current knowledge
In an attempt to adapt to the changes occurring and to the
growing needs of patients and to maximize the utilization ofcommunity pharmacists’ unique structured knowledge of a
drug’s safety proﬁle (side effects, interactions and con-
traindications) (Bush et al., 2009; McDonald et al., 2010;
Edmunds and Calnan, 2001; White and Latif, 2007), drug efﬁ-
cacy, patients’ preferences, monitoring outcomes, and drug
selection, the practice of new roles was introduced to the com-
munity pharmacy profession (Edmunds and Calnan, 2001;
Paudyal et al., 2010; Bryant et al., 2009; Inch et al., 2005)
Several studies have demonstrated that extending commu-
nity pharmacists’ roles could result in many beneﬁts for
patients which include the following: improvement in the qual-
ity of care, optimization of drug therapy (Smith et al., 2011), a
decrease in general practitioner workload, and a reduction in
the long-term healthcare costs (Giberson et al, 2011; Dunlop
and Shaw, 2002). The potential beneﬁts to community phar-
macists include improvements in their professional status and
job satisfaction and in the way they are paid (Edmunds and
Calnan, 2001; Bryant et al., 2009; Inch et al., 2005; Paudyal
et al., 2011). However, possible disadvantages from
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load and the development of a tense relationship between
pharmacists and physicians (Helper and Strand, 1990).
Extending community pharmacists’ roles started with the
introduction of the concept of pharmaceutical care (Aldous,
2003). Consequently, community pharmacists’ roles, in many
countries, were extended to include disease state management,
medicines use reviews (MURs) McDonald et al., 2010, health
assessment, monitoring, and screening, chronic disease man-
agement (Scahill et al., 2010; Edmunds and Calnan, 2001),
repeat dispensing (Edmunds and Calnan, 2001), minor ail-
ments management schemes (Edmunds and Calnan, 2001),
public health promotion and awareness (smoking cessation,
sexual health) (Edmunds and Calnan, 2001; Inch et al.,
2005), review and monitoring of prescribing guidelines, and
development of schemes to promote the safe use of medicines
in pregnancy and breastfeeding (Inch et al., 2005).
1.3. Speciﬁc problem
The new extended practice roles shifted the community phar-
macy practice emphasis from a product oriented to a patient
oriented one. The pharmaceutical care and ‘extended’ roles
are still not practiced optimally by the community pharma-
cists. Numerous studies have discussed the practice of commu-
nity pharmacy in the United Arab Emirates (UAE) and have
shown that most community pharmacists perform only patient
counseling.
1.4. Aim of the review
The aim was to review the current roles of community pharma-
cists in Abu Dhabi Emirate the capital of UAE.
1.5. Objective
The objective was to encourage community pharmacists
toward extending their practice roles and stimulate the policy
makers to foster laws to adapt the new changes.
2. Methods
We have performed a literature search looking for studies con-
ducted on community pharmacy and extended roles of com-
munity pharmacists in UAE and in developed countries
(Canada, New Zealand, United Kingdom-UK and United
States of America-USA). The type of study design and reasons
for choosing these studies and their suitability were all consid-
ered in the search criteria and inclusion thereafter. The type
and precise details of the interventions for each study and
respective group were deﬁned for the included studies. The
main factors that contribute to choice of interventions, inputs,
predictors and respective validity and reliability were taken
into account. Bias and other potential sources of bias, con-
founding, interactions, effect modiﬁers and imprecision were
identiﬁed and reported.
The sequence generation, group allocation, group balance,
equivalent treatment of participants/groups were rectiﬁed and
compared with report review criteria. The sampling method,
selection of participants/cases/groups and suitability of sam-
pling method were matched for set of studies and collation.The sample size calculation and suitability were compared
between similar study designs. The sampling protocol including
description and suitability of target/actual/sample population,
inclusion and exclusion criteria for participants/cases/groups,
and recruitment of participants/cases/groups were clearly
retrieved for the review. The reported studies were checked for
ethical matters such as informed consent, equity, privacy,
conﬁdentiality/anonymity, ethical approval, funding and con-
ﬂict of interest.
Furthermore, method used for data collection, suitability of
collection method and collection protocol (date, locations,
settings, personnel, materials and processes) were reviewed.
We also ensured/enhanced quality of measurement/instru-
mentation, management of non-participation, withdrawal
and incomplete/lost data for the included studies.3. Results
3.1. The international experience
One of the countries that took strong initiatives to extend com-
munity pharmacists’ roles is the United Kingdom (UK).
Pharmaceutical organizations have been involved in cam-
paigns for ‘re-professionalization’ of pharmacists - redeﬁning
their role to go beyond dispensing (McDonald et al., 2010;
Inch et al., 2005). The UK divided services provided by com-
munity pharmacists into essential, enhanced, and advanced
(Rapport et al., 2010). One example of an ‘essential service’
is repeat dispensing of chronic medication prescriptions
(Edmunds and Calnan, 2001). ‘Enhanced services’ include
minor ailments prescribing and involvement in smoking cessa-
tion programs (Bradley et al., 2008). ‘Advanced services’
include the MURs: a service provided to patients to review
their use and understanding of their medications thereby
improving their knowledge of their medications. It also
involves a check performed by pharmacists to identify, discuss,
and resolve poor or ineffective use of medications. In addition
to that, the pharmacist identiﬁes side effects and drug interac-
tions that may inﬂuence patient compliance and therefore
affect the clinical and cost effectiveness of the prescribed med-
ications (McDonald et al., 2010).
Even though the reclassiﬁcation of medications has
restricted the supply of many medicines by pharmacists with-
out a prescription, it has also allowed some prescription only
medications (POMs) to be supplied only by pharmacists as a
pharmacy medicine (PM). For example, medications for acute
minor illnesses have been reclassiﬁed from POMs to PMs;
similarly medications for more serious long-term illnesses-like
Simvastatin (primary-secondary prevention of coronary
events) and Sumatriptan (migraine treatment) - and med-
ications for treating irritable bowel syndrome, chlamydia,
and arthritis, have been reclassiﬁed to PMs (Bush et al.,
2009; McDonald et al., 2010; Paudyal et al., 2010). Patient
Group Directions (PGDs) have also been introduced to allow
pharmacists to supply certain POMs without a prescription
within strict protocols according to local requirements or to
supply medicines for indications not covered by the marketing
authorizations for other available over-the-counter-OTC
medicines (Bush et al., 2009; Paudyal et al., 2010).
In Scotland, a new community pharmacy contract was
implemented in 2005 allowing community pharmacists to
566 M.M. Sadek et al.present patients with more services via the Minor Ailment
Service (MAS), the Chronic Medication Service, the Acute
Medication Service, and the Pharmaceutical Public Health
Service (Paudyal et al., 2010; Inch et al., 2005). The MAS is
a service provided by community pharmacists to assist patients
in self-care for minor ailments (Paudyal et al., 2010). Paudyal
et al. (2010), have deﬁned these terms by referring to the World
Health Organization’s (WHO) deﬁnition of self-care (what
people do for themselves to establish and maintain health,
and to prevent and deal with illnesses) and to the Royal
Pharmaceutical Society of Great Britain’s (RPSGB) deﬁnition
of minor ailments (self-limiting conditions requiring little or no
medical intervention, such as cough, cold, and indigestion).
In New Zealand, the pharmaceutical society launched The
Ten Year vision for Pharmacists in 2004 (Scahill et al., 2010)
which called for pharmacists to practice enhanced cognitive
pharmaceutical services (CPS). Enhanced CPS are deﬁned as
‘professional services provided by pharmacist, using their skills
and knowledge to take an active role in contributing to patient
health through effective interaction with both patients and
other health professionals’ (Roberts et al., 2008).
In the USA, pharmacists now practice ‘new’ roles such as
administering immunizations, point-of-care testing (diagnostic
testing performed at or near the site of patient care for the
screening and monitoring of diseases), prescribing (initiate,
adjust, or discontinue) and managing medications for the
treatment of diseases such as dyslipidemia, congestive heart
failure, coronary artery disease, diabetes, asthma, hyperten-
sion, and end-stage renal disease; ordering, interpreting and
monitoring laboratory tests, formulating clinical assessments
and developing therapeutic plans, providing care coordination
and other health services for wellness and prevention of dis-
ease, and providing health maintenance information and edu-
cation (Giberson et al., 2011). In addition to that, pharmacists
in the USA can choose to obtain extra accreditation to become
specialized; examples of pharmacist specialties include nutri-
tion support, oncology, psychiatric, ambulatory care, diabetes
educator, advanced diabetes management, infection control
professional, professional in healthcare quality, professional
in healthcare information and management systems, and
chronic care professional (Giberson et al., 2011).
In the UK, Canada and the USA, prescribing rights have
been extended to community pharmacists (Abu Ruz et al.,
2012). There is a growing increase in the acceptance of changed
roles for pharmacists as prescribers and more expanded pre-
scribing rights have been granted in these countries.
3.2. Community pharmacy in the Middle East
The community pharmacy practice in most of the countries in
the Middle East is very similar to that of the United Arab
Emirates (UAE), where pharmaceutical care and ‘extended’
roles are still not practiced optimally or not practiced at all
(White and Latif, 2007; Hasan et al., 2011). However, some
of these countries, especially the UAE, have taken initiatives
to allow and prepare community pharmacists to practice ‘ex-
tended’ roles (Hasan et al., 2012).
Hasan and co-researchers have conducted many researches
related to the community pharmacy profession in the UAE
(Hasan et al., 2012, 2013). Due to the importance of their
work, a short summary of the methodology used by themand possible limitations should be introduced (this is not a
comprehensive critical appraisal of their work). Their ﬁrst
study investigated the community pharmacists’ workforce
characteristics and the perceived barriers to practicing profes-
sional (enhanced) services (Hasan et al., 2012). Their second
paper presented information collected from their ﬁrst study
about the type and frequency of services currently provided
in community pharmacies in the UAE (Hasan et al., 2012).
In their latest study, they developed, validated, and then used
a tool to assess patient (public in all the seven emirates of
UAE) satisfaction with current community pharmacy services
(Hasan et al., 2013).
In their ﬁrst and second studies, questionnaires were admi-
nistered by hand to community pharmacies, in all seven emi-
rates of UAE. Collecting information from such a diverse
population may have allowed results to be generalized; how-
ever, they did not take into account the diversity in healthcare
systems in each of the seven emirates which may have needed
further investigations. Calculating the sample size was based
on the number of community pharmacies (not the number of
community pharmacists). After sample size calculation, phar-
macies were chosen by systematic random sampling; then one
pharmacist from each pharmacy was chosen to respond. How
or on what basis this pharmacist was chosen was not made
clear. Nevertheless, if the pharmacist was chosen based on con-
venience/availability in the pharmacy at time of administration,
then generalization of results may be questioned (Smith, 1997).
Questionnaires were administered by undergraduate stu-
dents in Sharjah University in Sharjah Emirate (UAE). In
these studies some of the ‘enhanced’ services were investigated-
such as adverse drug reaction and medication errors identiﬁca-
tion and reporting and counseling in an open area- and are
actually ‘essential’ services to be provided by all community
pharmacists in Abu Dhabi (Health Authority Abu Dhabi,
2009a, 2009b; Health Authority Abu Dhabi CME/CPD
NEWS, 2010). That is why the provision of these services
may be different in Abu Dhabi from the rest of the other six
emirates, and further research on the provision of these ser-
vices particularly in Abu Dhabi would have been necessary.
In their latest study investigating public views of community
pharmacist services, the authors used a new tool to measure
satisfaction which still needs further validation. The sample
was chosen according to convenience. Even though random
sampling in this case was difﬁcult (Hasan et al., 2012) the
researchers realized that generalization of results should be
approached cautiously (Smith, 1997). Questionnaires were also
delivered by hand but via research assistants. Qualitative meth-
ods of data collection were not used in any of the three
researches. The investigators were the ﬁrst in the UAE to inves-
tigate these subjects using survey methods. They have covered
the topic of community pharmacy services from different per-
spectives (community pharmacists and the public), therefore,
are leading researchers on this topic in the UAE. Calculations
of sample size and justiﬁcation for the choice of the question-
naire administration method were explained well. Presentation
and discussion of results were comprehensive and unbiased.
3.3. Community pharmacy in Abu Dhabi
Abu Dhabi is the capital of the UAE. The UAE consists of
seven emirates (Abu Dhabi, Dubai, Fujairah, Umm
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healthcare systems differ from each other noticeably. The com-
munity of Abu Dhabi consists of local/national Emirati citi-
zens (16.5% of the population) and expatriates (people not
holding the UAE citizenship- non-UAE nationals- but resi-
dents in the UAE) from different countries such as Arab,
India, Pakistan, Philippines and other Asian countries,
United Kingdom, Russia, United States of America (USA)
and many other Europeans (Hasan et al., 2012). Health ser-
vices, provided by private or government facilities, and med-
ications dispensed to expatriates are paid for by insurance
companies. All types of insurance schemes must cover pay-
ment for basic healthcare services and medications prescribed
by doctors. However, the range of payment coverage is 20–
100% which differs as per each insurance scheme.
For UAE nationals, healthcare services and medications are
paid for by the National Health Insurance Company-Thiga and
Daman. The Department of Finance, Government of Abu
Dhabi, is responsible for the ﬁnancial reconciliation of all
healthcare services offered to UAE nationals and paid for by
Thiga-Daman (Health Authority Abu Dhabi, 2010c).
In Abu Dhabi, the Health Authority of Abu Dhabi
(HAAD) and the Ministry of Health (MOH) are responsible
for regulating the healthcare system (Authority Abu Dhabi
and Book 1: Legislation establishing the health sector.
[online]. Abu Dhabi, 2005). In Dubai, the Dubai Health
Authority (DHA) and the Ministry of Health (MOH) regulate
the healthcare system, the rest of the emirates (northern) are
regulated by the MOH alone. The government healthcare
facilities in Abu Dhabi are managed by Abu Dhabi Health
Services Company (SEHA). Community pharmacies are all
privately owned, and they are either small independently-
owned shops, chain franchised shops, or pharmacies belonging
to hospitals or medical centers (Hasan et al., 2012).
Pharmacies in the UAE are open for 7 days per week with
an average working day of 13 h. Most community pharmacists
(80%) work 6 days per week for 8–10 h per day (Hasan et al.,
2012). Most community pharmacists are initially qualiﬁed
from India, Egypt, the UAE, Philippines, and Jordan (Hasan
et al., 2012). For a pharmacist to practice in Abu Dhabi, a
licensing examination must be passed ﬁrst. The license can
only be renewed every year after attendance of a certain num-
ber of continuing medical education (CME) hours. This was
put as a requirement to improve and maintain the competency
of community pharmacists and to ensure all community phar-
macists in Abu Dhabi have the same skills and standards of
practice (this is important to overcome the diversity in their
learning backgrounds) (Health Authority Abu Dhabi, 2009c;
Dameh, 2009).4. Discussions
4.1. Pharmacy and pharmacist regulatory affairs
The pharmacy profession and practice in Abu Dhabi are gov-
erned by the UAE Federal Law number 4 and by circulars
regularly released by HAAD and the MOH. The law states
that community pharmacy owners must be UAE citizens with-
out speciﬁcation that they should be pharmacists. A recent
study has shown that 70% of community pharmacies were
owned by non-pharmacists (Hasan et al., 2012). The UAElaw deﬁnes the pharmacy profession as the preparation, com-
position, manufacturing, packing, selling, or distribution of
any medicine or pharmaceutical preparation for the protection
or treatment of humans or animals from diseases. According
to the law, pharmacists were not allowed to supply any medi-
cine or pharmaceutical preparation without a prescription (all
medicines were classiﬁed as POM or controlled drugs) (Health
Authority Abu Dhabi, 2010d) or practice any medical or nurs-
ing works, except for works related to ﬁrst aid (United Arab
Emirates Federal Law number 4, 1983).
Since 2005, many changes have been implemented to the
community pharmacy profession in Abu Dhabi. One of these
changes was the reclassiﬁcation of several medicines from
POM to pharmacist only medicines (PH-OM), over the coun-
ter pharmacy medicines (OTC-P), and medicines sold in phar-
macy and non-pharmacy outlets medicines (OTC-G)
Authority Abu Dhabi, 2011. In Abu Dhabi unlike the other
emirates, there are regular ‘surprise’ inspections on the practice
of community pharmacists. As a result, all rules are strictly fol-
lowed. For example, in some emirates oral contraceptives and
antibiotics (POMs) can sometimes be sold by the pharmacist
without a prescription- an act that would rarely happen in
Abu Dhabi.
A recent document was released by HAAD which clearly
outlined the professional competencies and roles of pharma-
cists for the ﬁrst time. It highlighted the importance of phar-
maceutical care and encouraged its practice, [Appendix II]
(Health Authority Abu Dhabi, 2010b). Several studies have
discussed the practice of community pharmacy in the UAE,
but not in Abu Dhabi speciﬁcally. These studies have shown
that around three-quarters of the pharmacies in the UAE dis-
pense fewer than 100 prescriptions (75%) and respond to fewer
than 100 requests for OTC medicines (69%) per day Hasan
et al., 2012. Specialized compounding for prescriptions occurs
in 32% of community pharmacies (Hasan et al., 2012).
Dispensing is mostly carried out by a pharmacy technician/as-
sistant, under the supervision of a pharmacist, to allow phar-
macists to fulﬁll administrative and managerial roles
(Dameh, 2009). Such roles include monitoring and reviewing
controlled drugs prescriptions, double checking prescriptions
for dispensing errors, dealing with insurance companies’
approvals and rejections, keeping track of stock and self-life
expiry (Hasan et al., 2012).
Studies have also shown that most community pharmacists
in the UAE only counsel patients regarding the dosage and fre-
quency of use of the medications they are purchasing; they
occasionally check for and advise on adverse reactions and
drug interactions, and usually only when asked by the patient
(Dameh, 2009). Results of a survey questionnaire distributed
to community pharmacists showed that 29% of the respon-
dents always offered patient information leaﬂets or other
written or printed material and 33% always used small
precautionary labels (for example take with food and do not
drive) when counseling patients. Counseling in an open area
was always provided by 28% of community pharmacists in
the UAE, while private counseling in a designated closed area
was always provided by 11% (Hasan et al., 2012). These
were all considered by this review as ‘enhanced professional’
roles.
The most recent study done by Hasan et al. (2013) used a
newly validated tool to assess patient satisfaction with commu-
nity pharmacy services in the UAE. Results showed that
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568 M.M. Sadek et al.members of the public were not satisﬁed with the counseling
services; a small percentage rated ‘very good’ or ‘excellent’
for the explanation they receive about their medication
(41%), the information provided about side effects of med-
ications (16%), and the interest shown by community pharma-
cists to help them make best use of their medication (30%).
Community pharmacists have limited immediate access to
up-to-date resources such as the British National Formulary
(BNF) Hasan et al., 2012. The turnover rate of pharmacists
in the community pharmacy sector is high. Researchers have
suggested this may affect continuous care delivery to patients
(Hasan et al., 2012). The community pharmacy services pro-
vided in the UAE were considered by some researchers as ‘tra-
ditional or product-focused with minimal or negligible
pharmaceutical care provided’ (Hasan et al., 2013).preventing prescribing errors. 4: Patient disease education. 5: Explaining
to patients use of medical devices. 6: Public health promotion. 7:
Medicines information to health professionals. 8: Reporting
Adverse Drug Reactions (ADRs), interactions, prescribing errors. 9:
Reviewing national circulars and international updates. 10: Selling and
counseling on over the counter (OTC) medicines. Reference:
Unpublished study.4.2. Health Authority Abu Dhabi (HAAD)’s initiatives
In 2010, HAAD surveyed community pharmacists, using an
online questionnaire, on their preferences toward extending
their counseling roles. They were asked questions on their:
demographic information, current practice, current phar-
macy layout, perspectives on future pharmacy licensing
requirements, support for reimbursement of additional
services they provide, interest in extending their counseling
roles for the management of different health conditions
(hypertension, diabetes, hyper-lipidemia, asthma, others),
and their opinion of the greatest challenge facing the exten-
sion of their counseling roles (see Appendix A-section 6 for
full survey questionnaire).
The results of this survey were not published but we were
able to obtain excerpts of it through personal communication
with HAAD employees. Following this survey, several pro-
grams have been developed to prepare community pharmacists
to undertake these extended counseling roles. Examples of such
programs include the Pharmacist Asthma Educator Program,
the Diabetes Management Educator Program, and the
American Pharmacist Association Immunization course for
pharmacists, and the Smoking Cessation Training (Health
Authority Abu Dhabi NEWS, 2011a, b; DMPR, 2010).
In addition to that, HAAD redeﬁned the scope of pharma-
cist roles to include some extended/enhanced roles such as:
screening, point of care testing and adult vaccination services,
medicines use management, and counseling patients on pre-
ventive health and lifestyle management strategies (Health
Authority Abu Dhabi NEWS, 2011a). HAAD’s mission is to
ensure reliable excellence in healthcare. It has put clear plans
to achieve this; these include increasing focus on public health
matters, developing and monitoring evidence-based clinical
policies, and training health professionals to comply with
international standards to deliver world-class quality care,
among others (Health Authority Abu Dhabi, 2011c). HAAD
has implemented part of its plans by extending the range of
services provided by community pharmacists to match some
of those provided by community pharmacists throughout the
world. There is a wider recognition that pharmacists are indis-
pensable in monitoring drug therapy, medication reconcilia-
tion, and providing responsible pharmaceutical care (Gulf
Medical University. College of Pharmacy, 2011). In advance
of making further plans to extend community pharmacists’
roles, and to ensure the triumph of these plans, it is importantto establish the views of community pharmacists in Abu Dhabi
on practicing extended roles and to gain understanding, to
explore roles and barriers and obtain in depth information
on what pharmacists see as preferred change strategies or facil-
itators to make the change (Roberts et al., 2005).
5. Conclusions
In an attempt to adapt to the changes occurring and to the
growing needs of patients and to maximize the utilization of
community pharmacists’ unique structured strategies and
health system reforms are needed to be introduced to the com-
munity pharmacy profession. There remains more rigorous
research needed to explore the extended roles of community
pharmacists and provide more evidence-based interventions
to inform the new practice.
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